David D Salcido1, Robert H Schmicker2, Noah Kime2, Jason E Buick3, Sheldon Cheskes4, Brian Grunau5, Stephanie Zellner6, Dana Zive7, Tom P Aufderheide6, Allison C Koller8, Heather Herren2, Jack Nuttall7, Matthew L Sundermann8, James J Menegazzi8. 1. University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: salcidodd@upmc.edu. 2. University of Washington, Seattle, WA, United States. 3. Rescu, Li Ka Shing Knowledge Institute, St. Michael's Hospital University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, Toronto ON, Canada. 4. Sunnybrook Center for Prehospital Medicine, Toronto, ON, Canada. 5. University of British Columbia, Vancouver, BC, Canada. 6. Medical College of Wisconsin, Milwaukee, WI, United States. 7. Oregon Health Sciences University, Portland, OR, United States. 8. University of Pittsburgh, Pittsburgh, PA, United States.
Abstract
BACKGROUND:Intra-resuscitation antiarrhythmic drugs may improve resuscitation outcomes, in part by avoiding rearrest, a condition associated with poor out-of-hospital cardiac arrest (OHCA) outcomes. However, antiarrhythmics may also alter defibrillation threshold. The objective of this study was to investigate the relationship between rearrest and intra-resuscitation antiarrhythmic drugs in the context of the Resuscitation Outcomes Consortium (ROC) amiodarone, lidocaine, and placebo (ALPS) trial. HYPOTHESIS: Rearrest rates would be lower in cases treated with amiodarone or lidocaine, versus saline placebo, prior to first return of spontaneous circulation (ROSC). We also hypothesized antiarrhythmic effects would be quantifiable through analysis of the prehospital electrocardiogram. METHODS: We conducted a secondary analysis of the ROC ALPS trial. Cases that first achieved prehospital ROSC after randomized administration of study drug were included in the analysis. Rearrest, defined as loss of pulses following ROSC, was ascertained from emergency medical services records. Rearrest rate was calculated overall, as well as by ALPS treatment group. Multivariable logistic regression models were constructed to assess the association between treatment group and rearrest, as well as rearrest and both survival to hospital discharge and survival with neurologic function. Amplitude spectrum area, median slope, and centroid frequency of the ventricular fibrillation (VF) ECG were calculated and compared across treatment groups. RESULTS:A total of 1144 (40.4%) cases with study drug prior to first ROSC were included. Rearrest rate was 44.0% overall; 42.9% for placebo, 45.7% for lidocaine, and 43.0% for amiodarone. In multivariable logistic regression models, ALPS treatment group was not associated with rearrest, though rearrest was associated with poor survival and neurologic outcomes. AMSA and median slope measures of the first available VF were associated with rearrest case status, while median slope and centroid frequency were associated with ALPS treatment group. CONCLUSION:Rearrest rates did not differ between antiarrhythmic and placebo treatment groups. ECG waveform characteristics were correlated with treatment group and rearrest. Rearrest was inversely associated with survival and neurologic outcomes.
RCT Entities:
BACKGROUND: Intra-resuscitation antiarrhythmic drugs may improve resuscitation outcomes, in part by avoiding rearrest, a condition associated with poor out-of-hospital cardiac arrest (OHCA) outcomes. However, antiarrhythmics may also alter defibrillation threshold. The objective of this study was to investigate the relationship between rearrest and intra-resuscitation antiarrhythmic drugs in the context of the Resuscitation Outcomes Consortium (ROC) amiodarone, lidocaine, and placebo (ALPS) trial. HYPOTHESIS: Rearrest rates would be lower in cases treated with amiodarone or lidocaine, versus saline placebo, prior to first return of spontaneous circulation (ROSC). We also hypothesized antiarrhythmic effects would be quantifiable through analysis of the prehospital electrocardiogram. METHODS: We conducted a secondary analysis of the ROC ALPS trial. Cases that first achieved prehospital ROSC after randomized administration of study drug were included in the analysis. Rearrest, defined as loss of pulses following ROSC, was ascertained from emergency medical services records. Rearrest rate was calculated overall, as well as by ALPS treatment group. Multivariable logistic regression models were constructed to assess the association between treatment group and rearrest, as well as rearrest and both survival to hospital discharge and survival with neurologic function. Amplitude spectrum area, median slope, and centroid frequency of the ventricular fibrillation (VF) ECG were calculated and compared across treatment groups. RESULTS: A total of 1144 (40.4%) cases with study drug prior to first ROSC were included. Rearrest rate was 44.0% overall; 42.9% for placebo, 45.7% for lidocaine, and 43.0% for amiodarone. In multivariable logistic regression models, ALPS treatment group was not associated with rearrest, though rearrest was associated with poor survival and neurologic outcomes. AMSA and median slope measures of the first available VF were associated with rearrest case status, while median slope and centroid frequency were associated with ALPS treatment group. CONCLUSION: Rearrest rates did not differ between antiarrhythmic and placebo treatment groups. ECG waveform characteristics were correlated with treatment group and rearrest. Rearrest was inversely associated with survival and neurologic outcomes.
Authors: Graham Nichol; Brian Leroux; Henry Wang; Clifton W Callaway; George Sopko; Myron Weisfeldt; Ian Stiell; Laurie J Morrison; Tom P Aufderheide; Sheldon Cheskes; Jim Christenson; Peter Kudenchuk; Christian Vaillancourt; Thomas D Rea; Ahamed H Idris; Riccardo Colella; Marshal Isaacs; Ron Straight; Shannon Stephens; Joe Richardson; Joe Condle; Robert H Schmicker; Debra Egan; Susanne May; Joseph P Ornato Journal: N Engl J Med Date: 2015-11-09 Impact factor: 91.245
Authors: Peter J Kudenchuk; Siobhan P Brown; Mohamud Daya; Laurie J Morrison; Brian E Grunau; Tom Rea; Tom Aufderheide; Judy Powell; Brian Leroux; Christian Vaillancourt; Jonathan Larsen; Lynn Wittwer; M Riccardo Colella; Shannon W Stephens; Mark Gamber; Debra Egan; Paul Dorian Journal: Am Heart J Date: 2014-03-01 Impact factor: 4.749
Authors: Paul Dorian; Dan Cass; Brian Schwartz; Richard Cooper; Robert Gelaznikas; Aiala Barr Journal: N Engl J Med Date: 2002-03-21 Impact factor: 91.245
Authors: Julia H Indik; Zacherie Conover; Meghan McGovern; Annemarie E Silver; Daniel W Spaite; Bentley J Bobrow; Karl B Kern Journal: J Am Coll Cardiol Date: 2014-09-30 Impact factor: 24.094
Authors: David D Salcido; Young-Min Kim; Lawrence D Sherman; Greggory Housler; Xiaoyi Teng; Eric S Logue; James J Menegazzi Journal: Resuscitation Date: 2011-10-01 Impact factor: 5.262
Authors: David D Salcido; James J Menegazzi; Brian P Suffoletto; Eric S Logue; Lawrence D Sherman Journal: Resuscitation Date: 2009-06-11 Impact factor: 5.262